Circulating Heparan Sulfate Proteoglycans as Biomarkers in Health and Disease.
Journal
Seminars in thrombosis and hemostasis
ISSN: 1098-9064
Titre abrégé: Semin Thromb Hemost
Pays: United States
ID NLM: 0431155
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
entrez:
1
4
2021
pubmed:
2
4
2021
medline:
29
10
2021
Statut:
ppublish
Résumé
Cell-surface heparan sulfate proteoglycans (HSPGs) play key roles in regulating cell behavior, cell signaling, and cell matrix interactions in both physiological and pathological conditions. Their soluble forms from glycocalyx shedding are not merely waste products, but, rather, bioactive molecules, detectable in serum, which may be useful as diagnostic and prognostic markers. In addition, as in the case of glypican-3 in hepatocellular carcinoma, they may be specifically expressed by pathological tissue, representing promising targets for immunotherapy. The primary goal of this comprehensive review is to critically survey the main findings of the clinical data from the last 20 years and provide readers with an overall picture of the diagnostic and prognostic value of circulating HSPGs. Moreover, issues related to the involvement of HSPGs in various pathologies, including cardiovascular disease, thrombosis, diabetes and obesity, kidney disease, cancer, trauma, sepsis, but also multiple sclerosis, preeclampsia, pathologies requiring surgery, pulmonary disease, and others will be discussed.
Identifiants
pubmed: 33794553
doi: 10.1055/s-0041-1725063
doi:
Substances chimiques
Biomarkers
0
Heparan Sulfate Proteoglycans
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
295-307Informations de copyright
Thieme. All rights reserved.
Déclaration de conflit d'intérêts
None declared.